Anti-anginal drugs are also known as anti-anginal agents. The management of angina is done through a variety of anti-anginal drugs. Angina is a heart condition in which the arteries of the heart, known as coronary arteries, become narrow. The primary symptom associated with angina is severe chest pain. Anti-anginal agents include nitrates, calcium antagonists, beta blockers, and Ranolazine. Examples of nitrates include nitroglycerin, isosorbide mono-nitrate, and isosorbide di-nitrate. These drugs help by relaxing the smooth muscle inside the blood vessels, making it wide and helping in the easy transfer of oxygen and blood to the heart. Examples of the calcium antagonists include verapamil, nimodipine, nifedipine, and diltiazem. These antagonists inhibit the contraction of the vascular smooth muscles due to their ability to inhibit calcium transfer into the cells. Examples of beta blockers include metoprolol, pindolol, propranolol, and atenolol. These drugs help in slowing down the heartbeat.
The exact way in which Ranolazine exerts its anti-anginal effect is not yet known. It is assumed that during cardiac repolarization, Ranolazine inhibits the ion channels. Anti-anginal drugs help in the treatment of Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasm, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Raynaud's syndrome is an indication of blockage of blood flow to the nose, ears, toes, and fingers, causing blood vessel spasms due to experiencing of strong emotions or cold temperatures. Pulmonary hypertension occurs due to narrowing of the small arteries of the lung, making it difficult for the blood to flow, thereby increasing the blood pressure. Under this condition, the right side of the heart pumps blood harder. Hence, the size of the heart increases over a period of time, resulting in heart failure. Heart failure is a condition in which the heart is not able to transfer nutrients and oxygen to the rest of the body. Heart attack is a condition of permanent damage or death of an area of the heart muscle due to inadequate supply of oxygen to that part of the heart. Esophageal spasms occur when the food in the esophagus does not effectively propel down to the stomach due to irregular contractions of muscles in the esophagus. The measures undertaken to prevent discomfort due to coronary heart disease or chest pain is known as angina pectoris prophylaxis. Rise in prevalence of Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula is projected to drive the anti-anginal drugs market during the forecast period. According to the Raynaud’s Association, 15 million to 30 million people in the U.S. are affected with Raynaud's syndrome.
The global anti-anginal drugs market can be segmented on the basis of mode of action, indication, dosage form, distribution channel, and region. Based on mode of action, the anti-anginal drugs market can be categorized into nitrates, calcium antagonists, beta blockers, and Ranolazine. In terms of indication, the anti-anginal drugs market can be classified into Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attack, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, and anal fissure and fistula. Based on dosage form, the anti-anginal drugs market can be divided into ointments and tablets. In terms of distribution channel, the anti-anginal drugs market can be bifurcated into retail pharmacies, online pharmacies, and hospital pharmacies.
Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/anti-anginal-drugs-market.html
Geographically, the global anti-anginal drugs market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America accounted for the dominant share of the anti-anginal drugs market in 2016 due to increase in prevalence of the heart failure and heart attack in the region. Europe constituted the next leading share of the anti-anginal drugs market share in 2016 owing to increase in prevalence of high blood pressure in the region. The anti-anginal drugs market in Asia Pacific is anticipated to expand at a significant rate during the forecast period. The anti-anginal drugs market in Middle East & Africa and Latin America is projected to expand during the forecast period owing to increase in initiatives undertaken by the governments to prevent incidences of heart attack and heart failure in these regions.
Key players operating in the global anti-anginal drugs market include Pfizer Inc., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and Gilead Sciences.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis
Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42011&source=atm
The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42011&source=atm